ClinicalXchange

Education through commercialization creates opportunities for peer-to-peer engagements

[ClinicalXchange @ClinicalXchange]

@MelanieSamson8, MPH, PhD, et. al. published in 10/17/22 @ASCO addresses traditional understanding of patients as merely recipients of health care services to their conceptualization as active participants in all aspects of their health. https://t.co/kr4GohP0Fq
#healthequity

[ClinicalXchange @ClinicalXchange]

@RyanGentzler, MD, MS & @Riess_MD answer questions on optimizing care of pts. w/ EGFR-mutated #NSCLC, insights on testing for EGFR mutations in early-stage NSCLC & importance of getting molecular test results before starting #immunotherapy.
https://t.co/meCe8XQOLu

[ClinicalXchange @ClinicalXchange]

@ClinicalXChange congratulates @SalmanPunekar & co-authors @ElaineShumMD , Cassandra Grello, Sally Lau & @VamsiVelcheti for this outstanding review, providing an excellent overview of current & future directions for #Immunotherapy in #lungcancer . https://t.co/wHfs7BaqlH

[ClinicalXchange @ClinicalXchange]

@JunMaoMD et. al. published “Integrative Medicine for Pain Management in #Oncology” in 9/19/22 @ASCO JCO. Publication provides evidence-based recs on integrative approaches to managing pain in #cancer pts. https://t.co/hlUVb7wuKz
#clinicaltrials #clinicalresearch #painmanagement

[ClinicalXchange @ClinicalXchange]

Amy S. Clark & co-authors @ErinCobain & Zoneddy Dayao published in @ASCO journal, addressing questions clinicians may face as they implement the updated recommendations into clinical practice.
https://t.co/4ItFCUrYMj
#cancer #oncology #ASCO #clinicaltrials #clinicalresearch

[ClinicalXchange @ClinicalXchange]

Plan ahead! As a service to our valued followers, @ClinicalXchange reminds everyone that housing for the @AACR 2023 Annual Meeting is now open. Reserve your hotel room now at https://t.co/2xv8ULmXpZ. We look forward to seeing you there!

#aacr2023 #aacr #cancerresearch

[ClinicalXchange @ClinicalXchange]

Don't miss 10/26/22 webinar on #SCLC, #ImmunoOncology in Untreated ES-SCLC, Treatment Approaches in Prev. Treated ES-SCLC & Key Clinical Trials in LS- & ES-SCLC. Details & free reg.: https://t.co/IHd0SJIcNG @HopkinsMedicine @hopkinskimmel
#oncology #cancer #smallcelllungcancer

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

We are proud of the Conquer Cancer Grants & Awards recipients who contributed to this study! Congratulations to Shanu Modi, MD, @prat_aleix, Nadia Harbeck, MD, PhD and all the researchers who presented this incredible breakthrough at #ASCO22 https://t.co/QlhqJNtKCC

[ClinicalXchange @ClinicalXchange]

@myESMO featured presentation by @EnriquetaFelip outlining HRQoL outcomes from CheckMate 816 phase 3 study. Along w/ previously reported efficacy & safety results, support use of NIVO + chemo as neoadjuvant treatment for resectable NSCLC. https://t.co/MYDX3E4UB4
#ESMO22

[ClinicalXchange @ClinicalXchange]

Listen to @ASCO’s JCO Cancer Stories podcast, “The Will to Go On,” by @sumitshahMD of @StanfordMed , exploring a patient’s will to live & recounting witnessing a powerful bond between a patient and her spouse. https://t.co/Pdot2P6DvR
#oncology #caregivers #Hospice

[ClinicalXchange @ClinicalXchange]

View this informative deck w/actionable content for #oncology #nurses on role of biomarker testing & practical application of recently approved targeted therapies in NSCLC. @AstraZeneca @LillyPad @Merck @Novartis @Regeneron @sanofi
https://t.co/KaNWgQyRy3
#cancer

[ClinicalXchange @ClinicalXchange]

Updated results of CORRECT Trial in @Annals_Oncology: STC1 is prognostic marker in pts. w/ refractory mCRC. High STC1 protein levels characterized a population of pts. w/ poor prognosis who benefit most from treatment w/ regorafenib. @myESMO @CHUdeBesancon
https://t.co/F21YkdjoJq

[ClinicalXchange @ClinicalXchange]

ICYMI: @NeilSkolnik, MD, and @Corinne Young discuss COPD exacerbations in this podcast, “COPD Exacerbations: A Clinical Conversation.” @KimmelCancerCtr @AstraZeneca
https://t.co/0bgvzFL80X
#COPD #lungdisease #lunghealth #pulmonology #respiratorytherapy

[ClinicalXchange @ClinicalXchange]

@EnriquetaFelip @IASLCplenary session: overall survival trend in favor of atezolizumab in PD-L1 TC ≥1% stage II-IIIA population, but not in all-randomized stage II-IIIA or ITT populations.
https://t.co/NyvHENIjWd
#WCLC22. #LCSM #CALGB #oncology #lungcancer

[ClinicalXchange @ClinicalXchange]

@BenjaminBesseMD at @IASLC: durvalumab + ceralasertib demo efficacy signal w/ tolerable safety profile in pts w/ adv./metastatic NSCLC following failure of anti-PD-1/PD-L1-containing immunotherapy & ≥1 platinum-doublet regimen. @GustaveRoussy
https://t.co/87yFXnczHb
#WCLC22

[ClinicalXchange @ClinicalXchange]

We congratulate the NADIM II clinical study team for their great work. These data were also featured in a recent plenary session at the @IASLC conference. @ASCO
#nivolumab #NSCLC #ctDNA #lungcancer

[International Lung Cancer Summit @LungSummit]

Results from phase II NADIM trial support neoadjuvant chemotherapy plus #nivolumab for resectable #NSCLC and the use of #ctDNA as a surrogate endpoint in terms of neoadjuvant treatment 🫁

See the study by Mariano Provencio, Atocha Romero & colleagues ➡️ https://t.co/YfmvmSCN9v

[ClinicalXchange @ClinicalXchange]

Congratulations to the TROPION-Lung02 study team for their recent presentation at the @IASLC conference.
#WCLC22 #LCSM #CALGB #oncology #NSCLC #LungCancer #clinicaltrials

[Daiichi Sankyo US @DaiichiSankyoUS]

#NEWS: Today at #WCLC22, we presented initial results from the TROPION-Lung02 trial assessing our investigational TROP2 directed ADC in a combination regimen in patients with advanced or metastatic #NSCLC: Learn more: https://t.co/GHqY9NeIuy #ClinicalTrials

[ClinicalXchange @ClinicalXchange]

Results from YESS study at recent @IASLC conference concluded that smokers receiving LHC in presence of co-located smoking cessation service experience quit rates considerably higher 3-months post-LHC.
https://t.co/SvgXf5ploX

#WCLC22 #LCSM #oncology #clinicaltrials

[ClinicalXchange @ClinicalXchange]

@AltorkiNasser in plenary session of @IASLC: patients w/ peripheral NSCLC 2 cm or less in size who have pathologically confirmed node-negative disease in major hilar & mediastinal lymph nodes, sub-lobar resection is non-inferior to lobectomy.
https://t.co/p7sfE0jPQ7
#WCLC22

[ClinicalXchange @ClinicalXchange]

Results of phase 3 POLO trial in @ASCO JCO: Hazard Ratio numerically favored patients receiving Olaparib. Data confer clinically meaningful benefits incl. increased time off chemo & long-term survival in subset of patients. @UChicago Medicine